"The
Report Frontier Pharma: Systemic Lupus Erythematosus - Identifying
and Commercializing First-in-Class Innovation provides information on
pricing, market analysis, shares, forecast, and company profiles for
key industry participants. - MarketResearchReports.biz"
The Systemic Lupus
Erythematosus (SLE) drug market is currently under-served by
non-generic, targeted therapies. Whilst the only Food and Drug
Administration (FDA)-approved biologic, Benlysta (belimumab),
generated sales of $111m in 2012, there is little evidence that the
drug’s performance is significantly superior to other B-cell
targeted therapies such as Rituxan (rituximab), which is often used
off-license to treat refractory SLE patients. Therapeutics entering
the market therefore do not face the staggering level of competition
from currently marketed programs as in other markets such as the
Rheumatoid Arthritis (RA) market. Emerging market entrants that
appear to offer significant therapeutic benefits are likely to cause
dramatic changes to the market landscape.
A growing understanding of the
signaling pathways underlying SLE pathophysiology including, but not
limited to, B cells, T cells and intracellular kinases, is
translating into a higher number of novel, and more importantly,
first-in-class targeted therapeutics entering the developmental
pipeline. In particular, a high level of investment in the
development of cytokine-blocking strategies is evident, as therapies
targeting the interferon pathway are relatively common in the
pipeline.
View Report At
:http://www.marketresearchreports.biz/analysis/185901
Scope
- The report analyzes the market for SLE therapeutics and the pipeline products in that market, with particular emphasis on first-in-class programs.
- A brief introduction to SLE, including symptoms, pathophysiology, disease scoring indices and overview of pharmacotherapy
- In-depth analysis and literature review on marketed products, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses, based on published clinical trials, as well as a reference table of drugs in terms of safety and efficacy
- Overview of how innovation products are contributing to the market for SLE therapeutics
- Comprehensive review of the pipeline for first-in-class therapies, which is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes
- The changing molecular target landscape between market and pipeline, and, in particular, focal points of innovation
- First-in-class molecular targets, highlighting early-stage programs for which clinical utility has yet to be evaluated, as well as an in-depth literature review on novel molecular targets
Reasons to buy
- The report will assist the business development strategies of companies that wish to develop novel therapies with improved benefits to existing treatments. It will also be of interest to companies seeking to expand their pipeline portfolio through licensing agreements and co-development deals. Primarily, the report will allow clients to identify and understand market opportunities and the emerging competitive environment. It will also allow you to
- Understand the SLE pipeline and the factors which indicate that it is becoming more innovative
- Understand the overall focal shifts in therapeutic molecular targets for the treatment of SLE
- Understand the distribution of the pipeline programs by phase of development, molecule type and molecular target
- Identify the list of first-in-class programs that are potentially open to deal-making opportunities
- Understand the first-in-class developmental programs and gauge the current clinical effectiveness based on animal models
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/185901
Table
of Contents
1
Table of Contents
1
Table of Contents 4
1.1
List of Tables 5
1.2
List of Figures 6
2
Introduction 7
2.1
The Case for Innovation in Systemic Lupus Erythematosus 7
2.2
Growing Opportunities for Biologic Products 7
2.3
Diversification of Molecular Targets 7
2.4
Innovative First-in-Class Product Developments Remain Attractive 8
2.5
Changes in the Clinical and Commercial Environment to be More
Favorable to Products Targeting Niche Patient Populations and
Indications 8
2.6
Sustained Innovation 8
3
Systemic Lupus Erythematosus 9
3.1
Disease Overview 9
3.2
Epidemiology 9
3.3
Disease Pathophysiology 10
3.4
Disease Symptoms 10
3.5
Environmental and Genetic Predisposition 11
3.6
Diagnosis 11
3.7
Disease Severity Assessments 12
3.7.1
PGA 12
3.7.2
SLEDAI 12
3.7.3
BILAG 13
3.7.4
SRI 13
3.8
Lupus Nephritis 13
3.9
Pharmacotherapy Algorithm 14
4
Clinical and Commercial Landscape 16
4.1
Corticosteroids 16
4.2
Antimalarials 16
4.3
Cytotoxic Chemotherapy 16
4.4
Biologics 17
4.4.1
Benlysta (belimumab) 17
4.5
Comparative Strengths and Weaknesses of Traditional Therapeutics 19
4.5.1
Corticosteroids vs Cytotoxic Therapeutics 19
4.5.2
Comparison of Immunosuppressants: Cyclosporine vs Azathioprine or
Cyclophosphamide 21
4.5.3
Cyclophosphamide vs Azathioprine 23
4.5.4
Cyclophosphamide vs Mycophenolate Mofetil 23
4.5.5
Mycophenolate Mofetil vs Azathioprine 23
4.5.6
Biologics vs Immunosuppressants 25
4.6
Current Unmet Needs in the Systemic Lupus Erythematosus Market 27
5
Assessment of Pipeline Product Innovation 28
5.1
Overview of Pipeline Products for Systemic Lupus Erythematosus 28
5.2
Frequently Targeted Molecular Target Families 29
5.3
Comparative Distribution of Programs between the Systemic Lupus
Erythematosus Market and Pipeline by Therapeutic Target Family 30
5.4
Comparative Efficacy and Safety of Pipeline Programs 31
5.5
Comparative Distribution of Programs with First-in-Class and
Established Targets 33
5.6
Pipeline Programs Targeting Established Molecular Targets 35
5.7
First-in-class Pipeline Programs with Novel Molecular Targets 37
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment